Anzeige
Mehr »
Login
Donnerstag, 27.01.2022 Börsentäglich über 12.000 News von 667 internationalen Medien
Jerusalem Post: Eine große Hürde für den CBD-Pharmabereich wurde von InnoCan Pharma eingerissen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CV9C ISIN: BMG0360L1000 Ticker-Symbol: 2QA 
Tradegate
26.01.22
15:42 Uhr
1,160 Euro
+0,050
+4,50 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALTAMIRA THERAPEUTICS LTD Chart 1 Jahr
5-Tage-Chart
ALTAMIRA THERAPEUTICS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,1101,13026.01.
1,0801,13026.01.

Aktuelle News zur ALTAMIRA THERAPEUTICS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrAltamira Therapeutics nasal spray Bentrio approved in Malaysia-
FrAltamira Therapeutics Announces Approval of Bentrio Nasal Spray in Malaysia177HAMILTON, BERMUDA / ACCESSWIRE / January 21, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection...
► Artikel lesen
13.01.Altamira Therapeutics appoints chief development officer; gets NIH grant2
ALTAMIRA THERAPEUTICS Aktie jetzt für 0€ handeln
13.01.Altamira Therapeutics Provides Update on RNA Therapeutics Program126Covadonga Pañeda, Ph.D., to join leadership team as Chief Development Officer for RNA therapeuticsReceipt of NIH grant to help advance siRNA delivery platform for use in extrahepatic inflammatory disordersHAMILTON...
► Artikel lesen
05.01.Altamira Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference114HAMILTON, BERMUDA / ACCESSWIRE / January 5, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection...
► Artikel lesen
29.12.21Altamira Therapeutics rises 26% over positive update on antiviral nasal spray Bentrio7
29.12.21MedAvail, Altamira Therapeutics leads healthcare gainers; Chembio Diagnostics, Gamida Cell among major losers4
29.12.21Altamira Therapeutics Provides Update on Bentrio Program301Bentrio becoming available through Amazon platform in key German marketDefinite Marketing and Distribution Agreement signed for six Asian countriesPreparations for COVID-19 trial advancingCompany to...
► Artikel lesen
28.12.21Altamira Therapeutics, Regencell Bioscience leads healthcare gainers; Biofrontera, Microbot Medical among major losers29
16.12.21Altamira Therapeutics Announces Randomization of First Patients in Bentrio Trial in House Dust Mite Allergy179HAMILTON, BERMUDA / ACCESSWIRE / December 16, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection...
► Artikel lesen
16.12.21Altamira Therapeutics Ltd. - 6-K, Report of foreign issuer-
01.12.21Altamira Therapeutics Announces Randomization of First Patient in Bentrio Trial in Seasonal Allergic Rhinitis258HAMILTON, BERMUDA / ACCESSWIRE / December 1, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection...
► Artikel lesen
16.11.21Altamira Therapeutics files for $79M mixed securities offering8
15.11.21Altamira Therapeutics Announces Poster Presentations at AHA Scientific Sessions 2021248Altamira's peptide-based platform for extrahepatic RNA delivery shows promising results in management of abdominal aortic aneurysm in murine disease modelssiRNA polyplexes targeting NF-kB suppress disease...
► Artikel lesen
12.11.21CYTO Stock: The Nasal Spray News Blowing Altamira Therapeutics Sky-High Today10
12.11.21Altamira Therapeutics, SOC Telemed leads healthcare gainers; Oncorus, Acutus Medical amog major losers4
12.11.21Altamira Therapeutics Reports Positive In vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Delta Variant394Significant reduction of infectious viral titer in human nasal epithelium model with either prophylactic or therapeutic applicationResults provide further confirmation for broad applicability in viral...
► Artikel lesen
25.10.21Altamira Therapeutics and Wellesta Collaborate for Marketing and Distribution of Bentrio in Six Key Asian Markets308HAMILTON, BERMUDA / ACCESSWIRE / October 25, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection...
► Artikel lesen
14.10.21Altamira Therapeutics Receives FDA Acceptance for Bentrio 510(k) Application290HAMILTON, BERMUDA / ACCESSWIRE / October 14, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs through RNA therapeutics...
► Artikel lesen
06.10.21Altamira Therapeutics to Participate in A.G.P.'s Virtual Biotech and Specialty Pharma Conference228HAMILTON, BERMUDA / ACCESSWIRE / October 6, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs through RNA therapeutics...
► Artikel lesen
Seite:  Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1